Optimum treatment of congenital cytomegalovirus infection

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 5, 2016, Pages 479-488

  Leruez Ville, Marianne ^a,b   Ville, Yves ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

congenital; Cytomegalovirus; hyperimmmune globulin; valacyclovir; valganciclovir

Indexed keywords

ACICLOVIR; BENZIMIDAVIR; BRINCIDOFOVIR; CIDOFOVIR; FOSCARNET SODIUM; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HYPERIMMUNE GLOBULIN; LETERMOVIR; PLACEBO; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA; ANTIVIRUS AGENT;

AMNIOCENTESIS; ANEMIA; CARCINOGENICITY; CONGENITAL INFECTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DENVER DEVELOPMENTAL SCREENING TEST; DIARRHEA; DNA DETERMINATION; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FETUS ECHOGRAPHY; GENOTOXICITY; HUMAN; HYPERTRANSAMINASEMIA; INFECTION PREVENTION; NEUROLOGIC DISEASE; NEUTROPENIA; NEWBORN CARE; NONHUMAN; PASSIVE IMMUNIZATION; PATIENT MONITORING; PATIENT SELECTION; PERINATAL PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTNATAL CARE; PREGNANCY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SALIVA ANALYSIS; SCREENING TEST; TERATOGENICITY; TESTIS INJURY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; VERTICAL TRANSMISSION; VIRUS LOAD; CYTOMEGALOVIRUS INFECTIONS; FEMALE; IMMUNOLOGY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; TRENDS;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; PERIPARTUM PERIOD; POSTNATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE;

EID: 84988358020     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2016.1173540     Document Type: Review

References (75)

1. A.Kenneson, M.J.Cannon Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007 Aug;17(4):253–276.
2. P.D.Griffiths. Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect Dis. 2012 Oct;12(10):790–798.•• Comprehensive review on the challenges for HCMV vaccination.
3. S.C.Dollard, S.D.Grosse, D.S.Ross. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007 Oct;17(5):355–363.
4. J.J.C.de Vries, E.W.van Zwet, F.W.Dekker, et al. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection:a population-based prediction model. Rev Med Virol. 2013 Jul;23(4):241–249.• Interesting model showing the high frequency and burden of congenital infection after maternal secondary infection.
5. C.Wang, X.Zhang, S.Bialek, et al. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis. 2011 Jan 15;52(2):e11–3.
6. J.F.Modlin, A.M.Arvin, P.Fast, et al. Vaccine development to prevent cytomegalovirus disease:report from the National Vaccine Advisory Committee. Clin Infect Dis. 2004 Jul 15;39(2):233–239.
7. R.F.Pass, C.Zhang, A.Evans, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009 Mar 19;360(12):1191–1199.
8. P.D.Griffiths, A.Stanton, E.McCarrell, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients:a phase 2 randomised placebo-controlled trial. Lancet Lond Engl. 2011 Apr 9;377(9773):1256–1263.
9. M.A.Kharfan-Dabaja, M.Boeckh, M.B.Wilck, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation:a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012 Apr;12(4):290–299.
10. M.J.Cannon, P.D.Griffiths, V.Aston, et al. Universal newborn screening for congenital CMV infection:what is the evidence of potential benefit? Rev Med Virol. 2014 Sep;24(5):291–307.
11. D.W.Kimberlin, C.-Y.Lin, P.J.Sánchez, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system:a randomized, controlled trial. J Pediatr. 2003 Jul;143(1):16–25.
12. S.E.Oliver, G.A.Cloud, P.J.Sánchez, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol. 2009 Dec;46(Suppl 4):S22–6.
13. D.W.Kimberlin, P.M.Jester, P.J.Sánchez, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015 Mar 5;372(10):933–943.•• Shows the efficacy and limits of postnatal six months valganciclovir therapy in a randomized controlled study.
14. D.W.Kimberlin, E.P.Acosta, P.J.Sánchez, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008 Mar 15;197(6):836–845.
15. F.Natale, B.Bizzarri, V.Cardi, et al. Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection. Ital J Pediatr. 2015;41:26.
16. S.B.Boppana, S.A.Ross, M.Shimamura, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med. 2011 Jun 2;364(22):2111–2118.• First large scale report of the efficacy of CMV neonatal screening in saliva.
17. S.A.Ross, A.Ahmed, A.L.Palmer, et al. Detection of congenital cytomegalovirus infection by real-time polymerase chain reaction analysis of saliva or urine specimens. J Infect Dis. 2014 Nov 1;210(9):1415–1418.
18. R.Manara, L.Balao, C.Baracchini, et al. Brain magnetic resonance findings in symptomatic congenital cytomegalovirus infection. Pediatr Radiol. 2011 Aug;41(8):962–970.
19. L.B.Rivera, S.B.Boppana, K.B.Fowler, et al. Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics. 2002 Oct;110(4):762–767.
20. J.Amir, M.Schwarz, I.Levy, et al. Is lenticulostriated vasculopathy a sign of central nervous system insult in infants with congenital CMV infection? Arch Dis Child. 2011 Sep;96(9):846–850.
21. E.Bilavsky, M.Schwarz, J.Pardo, et al. Lenticulostriated vasculopathy is a high-risk marker for hearing loss in congenital cytomegalovirus infections. Acta Paediatr. 2015 Sep;104(9):e388–94. Oslo Nor 1992.
22. A.Lackner, A.Acham, T.Alborno, et al. Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection:four to 10 year follow up. J Laryngol Otol. 2009 Apr;123(4):391–396.
23. S.Luck, A.Lovering, P.Griffiths, et al. Ganciclovir treatment in children:evidence of subtherapeutic levels. Int J Antimicrob Agents. 2011 May;37(5):445–448.
24. K.Y.Choi, B.Sharon, H.H.Balfour, et al. Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection. J Clin Virol. 2013 Aug;57(4):356–360.
25. R.Thust, M.Schacke, P.Wutzler. Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine Nucleoside Analogues. Antiviral Res. 1996 Jun;31(1–2):105–113.
26. R.Thust, M.Tomicic, R.Klöcking, et al. Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1:implications for gene therapeutic approaches. Cancer Gene Ther. 2000 Jan;7(1):107–117.
27. P.Wutzler, R.Thust. Genetic risks of antiviral nucleoside analogues–a survey. Antiviral Res. 2001 Feb;49(2):55–74.
28. J.Neyts, G.Jähne, G.Andrei, et al. In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine. Antimicrob Agents Chemother. 1995 Jan;39(1):56–60.
29. A.S.Faqi, A.Klug, H.J.Merker, et al. Ganciclovir induces reproductive hazards in male rats after short-term exposure. Hum Exp Toxicol. 1997 Sep;16(9):505–511.
30. S.Kadambari, E.J.Williams, S.Luck, et al. Evidence based management guidelines for the detection and treatment of congenital CMV. Early Hum Dev. 2011 Nov;87(11):723–728.• Comprehensive guidelines for neonatal congenital infection treatment.
31. M.G.Revello, E.Genini, G.Gorini, et al. Comparative evaluation of eight commercial human cytomegalovirus IgG avidity assays. J Clin Virol. 2010 Aug;48(4):255–259.
32. M.Leruez-Ville, Y.Sellier, L.J.Salomon, et al. Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy:a retrospective cohort. Clin Infect Dis. 2013 May;56(10):1428–1435.
33. Y.Sellier, T.Guilleminot, Y.Ville, et al. Comparison of the LIAISON(®) CMV IgG avidity II and the VIDAS(®) CMV IgG avidity II assays for the diagnosis of primary infection in pregnant women. J Clin Virol. 2015 Nov;72:46–48.
34. M.G.Revello, E.Fabbri, M.Furione, et al. Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection:a 20-year experience. J Clin Virol. 2011 Apr;50(4):303–307.
35. A.Chatterjee, C.J.Harrison, W.J.Britt, et al. Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis. 2001 Jun 1;183(11):1547–1553.
36. Y.Weisblum, A.Panet, Z.Zakay-Rones, et al. Modeling of human cytomegalovirus maternal-fetal transmission in a novel decidual organ culture. J Virol. 2011 Dec;85(24):13204–13213.
37. D.Lilleri, A.Kabanova, M.G.Revello, et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PloS One. 2013;8(3):e59863.
38. G.Nigro, S.P.Adler, R.La Torre, et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005 Sep 29;353(13):1350–1362.
39. G.Nigro, S.P.Adler, G.Parruti, et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy–a case-control study of the outcome in children. J Infect Dis. 2012 Jan 15;205(2):215–227.
40. S.Visentin, R.Manara, L.Milanese, et al. Early primary cytomegalovirus infection in pregnancy:maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis. 2012 Aug;55(4):497–503.
41. M.G.Revello, T.Lazzarotto, B.Guerra, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014 Apr 3;370(14):1316–1326.•• Shows the lack of efficacy of hyperimmune globulin to prevent CMV vertical transmission from the mother to the fetus in a randomized controlled study.
42. E.van Leeuwen, K.Oude Rengerink, E.Pajkrt. Hyperimmune globulin to prevent congenital CMV infection. N Engl J Med. 2014 Jun 26;370(26):2543–2544.
43. K.Hamprecht, K.-O.Kagan, R.Goelz. Hyperimmune globulin to prevent congenital CMV infection. N Engl J Med. 2014 Jun 26;370(26):2543.
44. P.A.Thürmann, C.Sonnenburg-Chatzopoulos, R.Lissner. Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. Eur J Clin Pharmacol. 1995;49(3):237–242.
45. G.Benoist, M.Leruez-Ville, J.F.Magny, et al. Management of pregnancies with confirmed cytomegalovirus fetal infection. Fetal Diagn Ther. 2013;33(4):203–214.
46. D.E.Noyola, G.J.Demmler, C.T.Nelson, et al. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr. 2001 Mar;138(3):325–331.
47. G.Ancora, M.Lanari, T.Lazzarotto, et al. Cranial ultrasound scanning and prediction of outcome in newborns with congenital cytomegalovirus infection. J Pediatr. 2007 Feb;150(2):157–161.
48. G.Benoist, L.J.Salomon, F.Jacquemard, et al. The prognostic value of ultrasound abnormalities and biological parameters in blood of fetuses infected with cytomegalovirus. BJOG Int J Obstet Gynaecol. 2008 Jun;115(7):823–829.
49. G.Benoist, L.J.Salomon, M.Mohlo, et al. Cytomegalovirus-related fetal brain lesions:comparison between targeted ultrasound examination and magnetic resonance imaging. Ultrasound Obstet Gynecol. 2008 Dec;32(7):900–905.
50. O.Picone, I.Simon, A.Benachi, et al. Comparison between ultrasound and magnetic resonance imaging in assessment of fetal cytomegalovirus infection. Prenat Diagn. 2008 Aug;28(8):753–758.
51. S.Lipitz, Y.Yinon, G.Malinger, et al. Risk of cytomegalovirus-associated sequelae in relation to time of infection and findings on prenatal imaging. Ultrasound Obstet Gynecol. 2013 May;41(5):508–514.
52. E.Fabbri, M.G.Revello, M.Furione, et al. Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood. BJOG Int J Obstet Gynaecol. 2011 Mar;118(4):448–456.
53. M.Leruez-Ville, J.J.Stirnemann, Y.Sellier, et al. Prediction of neonatal outcome in congenital cytomegalovirus infection at the time of prenatal diagnosis. Am J Obstet Gynecol. Forthcoming 2016.
54. C.Desveaux, J.Klein, M.Leruez-Ville, et al. Identification of symptomatic fetuses infected with cytomegalovirus using amniotic fluid peptide biomarkers. PLoS Pathog. 2016 Jan;12(1):e1005395.
55. F.Nihi, D.Moreira, A.C.Santos Lourenço, et al. Testicular effects following in utero exposure to the antivirals acyclovir and ganciclovir in rats. Toxicol Sci Off J Soc Toxicol. 2014 May;139(1):220–233.
56. G.M.Pacifici. Transfer of antivirals across the human placenta. Early Hum Dev. 2005 Aug;81(8):647–654.
57. R.C.Brandy, M.R.Schleiss, D.P.Witte, et al. Placental transfer of ganciclovir in a woman with acquired immunodeficiency syndrome and cytomegalovirus disease. Pediatr Infect Dis J. 2002 Aug;21(8):796–797.
58. B.W.Miller, T.K.Howard, J.A.Goss, et al. Renal transplantation one week after conception. Transplantation. 1995 Dec 15;60(11):1353–1354.
59. M.D.Pescovitz. Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. Transplantation. 1999 Mar 15;67(5):758–759.
60. D.P.Puliyanda, N.S.Silverman, D.Lehman, et al. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient. Transpl Infect Dis Off J Transplant Soc. 2005 Jun;7(2):71–74.
61. A.S.Tyms, E.M.Scamans, H.M.Naim. The in vitro activity of acyclovir and related compounds against cytomegalovirus infections. J Antimicrob Chemother. 1981 Jul;8(1):65–72.
62. D.Lowance, H.H.Neumayer, C.M.Legendre, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International valacyclovir cytomegalovirus prophylaxis transplantation study group. N Engl J Med. 1999 May 13;340(19):1462–1470.
63. P.D.Griffiths, J.E.Feinberg, J.Fry, et al. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis. 1998 Jan;177(1):57–64.
64. V.C.Emery, C.Sabin, J.E.Feinberg, et al. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease:baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis. 1999 Sep;180(3):695–701.
65. I.Chahoud, R.Stahlmann, G.Bochert, et al. Gross-structural defects in rats after acyclovir application on day 10 of gestation. Arch Toxicol. 1988 Aug;62(1):8–14.
66. K.M.Stone, R.Reiff-Eldridge, A.D.White, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure:conclusions from the international acyclovir pregnancy registry, 1984-1999. Birt Defects Res A Clin Mol Teratol. 2004 Apr;70(4):201–207.
67. B.Pasternak, A.Hviid. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA J Am Med Assoc. 2010 Aug 25;304(8):859–866.•• Shows that acyclovir taken at any time in pregnancy does not increase the risk of birth defects.
68. F.M.Marty, M.Boeckh. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr Opin Virol. 2011 Dec;1(6):555–562.
69. F.M.Marty, P.Ljungman, G.A.Papanicolaou, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants:a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011 Apr;11(4):284–292.
70. D.J.Winston, F.Saliba, E.Blumberg, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients:a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012 Nov;12(11):3021–3030.
71. R.F.Chemaly, A.J.Ullmann, S.Stoelben, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 May 8;370(19):1781–1789.
72. F.M.Marty, D.J.Winston, S.D.Rowley, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013 Sep 26;369(13):1227–1236.
73. F.Jacquemard, M.Yamamoto, J.-M.Costa, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG Int J Obstet Gynaecol. 2007 Sep;114(9):1113–1121.
74. C.V.Fletcher, J.A.Englund, C.K.Edelman, et al. Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother. 1991 May;35(5):938–943.
75. R.Simon. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1–10.